Clinical trials: Neck Cancer
Head and Neck Neoplasms
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy.
- Trial name
- NCT01856478
- Testing
- Methotrexate, Afatinib
- Where
- 53 sites in China, Egypt and 6 more
- Volunteers
- 340 people
- Sponsor
- Boehringer Ingelheim
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Non Small Cell Lung Cancer, Cutaneous Melanoma
RTX-224 Monotherapy in Patients With Solid Tumors
This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT05219578
- Testing
- RTX-224
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Rubius Therapeutics
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Non-curable Patients With SCCHN
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
- Trial name
- NCT00542308
- Testing
- Zalutumumab
- Where
- 48 sites in United States, Austria and 9 more
- Volunteers
- 90 people
- Sponsor
- Genmab
Salivary Gland Tumor, Urothelial Carcinoma
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that…
- Conditions
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
- Trial name
- NCT04969835
- Testing
- AVA6000
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 158 people
- Sponsor
- Avacta Life Sciences Ltd
Recurrent or Metastatic Cervical Cancer
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end point is safety.
- Trial name
- NCT04868708
- Testing
- AK104, Bevacizumab, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Akeso
Cervical Cancer
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer.
- Trial name
- NCT07497074
- Testing
- JSKN033, Platinum, Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Oral Mucositis, Head and Neck Cancer
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
- Trial name
- NCT00574860
- Testing
- EN3285, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Cervical Cancer
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2- combination…
- Trial name
- NCT03894215
- Testing
- AGEN2034, AGEN1884
- Where
- 68 sites in United States, Brazil and 5 more
- Volunteers
- 211 people
- Sponsor
- Agenus Inc.
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis in subjects with locally advanced head and…
- Trial name
- NCT00131638
- Testing
- Palifermin
- Volunteers
- 241 people
- Sponsor
- Amgen
Head and Neck Neoplasms
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
- Trial name
- NCT02254018
- Testing
- bivatuzumab mertansine
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Cancer, Esophagogastric Junction Cancer
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer…
- Trial name
- NCT04752358
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 3 people
- Sponsor
- Adaptimmune
Squamous Cell Carcinoma of the Head and Neck
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Protocol VRXP-A106 will enroll patients with Stage II-IVA head and neck cancer patients who will be treated with surgical resection.
- Trial name
- NCT02124850
- Testing
- Motolimod, Cetuximab, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Celgene
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
This is a first in human, multicenter, open label, Phase 1a and 1b dose-escalation and dose-expansion study to establish the maximum tolerated dose, recommended Phase 2 dose, and evaluate the safety and tolerability of QD oral…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT05121948
- Testing
- HC-7366
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- HiberCell, Inc.
Head and Neck Cancer
Phase II Study of TAS-106 to Treat Head and Neck Cancer
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
- Trial name
- NCT00737360
- Testing
- TAS-106
- Where
- 5 sites in United States, Hong Kong and 2 more
- Volunteers
- 27 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Cancer, Cancer Central Nervous System
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy…
- Conditions
- Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal
- Trial name
- PREMIER (NCT05406167)
- Testing
- Registry - Observational
- Where
- 5 sites in United States
- Volunteers
- 500 people
- Sponsor
- RefleXion Medical
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.